Fact CheckerSign in

NCT06810089Completed

Examination of Lacrimal Sac and Nasal Mucosa Preparations Taken in Dacryocystorhinostomy Surgery of Patients With Nasolacrimal Duct Obstruction and Comparison of Clinical Groups With Each Other

Source: ClinicalTrials.gov · Last updated 5 Feb 2025

Brief summary (registry, in English)

The goal of this observational study is to investigate etiology and pathogenesis of nasolacrimal duct obstruction and dacryocystitis in different adult clinic groups. The main question it aims to answer is: Are there differences in terms of staining scores between groups? There are 4 groups: Cohort 1: Primary Nasolacrimal Duct Obstruction without any dacryocystitis history Cohort 2: Primary Nasolacrimal Duct Obstruction with dacryocystitis history Cohort 3:Traumatic Nasolacrimal Duct Obstruction Cohort 4:Nasolacrimal Duct Obstruction with Membranes in the Nasolacrimal Sac

Status (registry)
Completed
Study type
Observational
Enrollment
78 (actual)
First submitted
30 Jan 2025
Start date
15 May 2023
Primary completion date
28 Feb 2024
Lead sponsor
Uludag University
NCT number
NCT06810089

What you commit to

  • Study type: Observational
  • Participants enrolled: 78
  • From 15 May 2023 to the primary completion date, 28 Feb 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • \-

Who the study is looking for

  • \-

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Bursa Uludag University, School of Medicine
Coordinator of this site? Confirm its status
BursaTurkey (Türkiye)Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.